DUBLIN–(BUSINESS WIRE)–The “Global Hidradenitis Suppurativa Market: Analysis By Patients, By Drugs (Povorcitinib, Bimekizumab, Sonelokimab), By Region Size (The US, Europe, Rest of the World) & Forecast with Impact Analysis of COVID-19 and Forecast up to 2030” report has been added to ResearchAndMarkets.com’s offering. In 2022, the global hidradenitis suppurativa market was valued at US$1.46 billion, … [Read more…]

-Companies to Create World-Class Ophthalmology Entity- -Lead Program, Avacincaptad Pegol for the Potential Treatment of Geographic Atrophy with PDUFA Goal Date of August 19, 2023– -Acquisition advances Astellas’ Primary Focus on “Blindness & Regeneration”- -Acquisition price of US$40 per share in cash, representing a total equity value of approximately US$5.9 billion- TOKYO & PARSIPPANY, N.J.–(BUSINESS … [Read more…]

PRINCTON, N.J.–(BUSINESS WIRE)–UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the first and largest post-commercial utilization review of JELMYTO® (mitomycin) for pyelocalyceal solution presented at the American Urological Association Meeting 2023 in Chicago, IL. … [Read more…]

MEMPHIS, Tenn.–(BUSINESS WIRE)–Emmy-nominated NFL Network host Rich Eisen suited up and sprinted for St. Jude Children’s Research Hospital® this week during his annual Run Rich Run event. Joining him were St. Jude patients and NFL ambassadors supporting the lifesaving mission of St. Jude: Finding cures. Saving children.® Now in its 19th year, Run Rich Run … [Read more…]

Data from studies encompassing over 100,000 prostate cancer patients presented at American Urology Association (AUA) 2023 Annual Meeting SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced that new data presented at the American Urological Association (AUA) 2023 Annual Meeting validate the real-world performance and clinical utility of the company’s Decipher Prostate Genomic Classifier. The … [Read more…]

This new treatment provides adults living with schizophrenia a long-acting formulation that offers flexible 1- and 2-month dosing intervals1 In a Phase 3 clinical trial, UZEDY demonstrated up to 80% reduction in risk of schizophrenia relapse versus placebo1 UZEDY is a subcutaneous injection from a pre-filled syringe with a 21-gauge needle PARSIPPANY, N.J., TEL AVIV … [Read more…]

Sunday, April 30, 1:00 p.m. – 5:00 p.m. St. Gregory Hotel WASHINGTON–(BUSINESS WIRE)–On Sunday, April 30th, speakers and panelists from across the country will be in Washington, DC to participate in the Housing Affordability, Rent Control and Homelessness Conference. Experts and advocacy leaders will illustrate how they successfully campaigned for solutions to the affordable housing … [Read more…]

BURLINGAME, Calif.–(BUSINESS WIRE)–Innoviva, Inc. (NASDAQ: INVA) (“Innoviva” and “the Company”) and George Bickerstaff, III, Chairman of the Board of Directors of the Company (the “Board”) today announced that Mr. Bickerstaff would not stand for reelection at the Company’s 2023 Annual Meeting. Following the Meeting, assuming that all other members of the Board are reelected, the … [Read more…]

RAHWAY, N.J.–(BUSINESS WIRE)–$MRK #MRK–Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC), by a vote of 11 to 1 with one abstention, supported FDA approval of LYNPARZA plus abiraterone and prednisone or prednisolone (abi/pred) for the … [Read more…]

BOCA RATON, Fla.–(BUSINESS WIRE)–Cross Country Healthcare, Inc. (the “Company”) (Nasdaq: CCRN) announced today that it is scheduled to participate in the Benchmark Healthcare House Call Virtual Conference taking place on May 23, 2023. John Martins, President & Chief Executive Officer, William J. Burns, Executive Vice President & Chief Financial Officer, and Josh Vogel, Vice President, … [Read more…]